PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum chemotherapy and a prior PARP inhibitor. The goal was to see if the combo could shrink tumors or slow cancer g…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New hope for hard-to-treat ovarian cancer: drug combo shows promise in early trial
Disease control CompletedThis study tested a new drug called ZN-c3, alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to see if the treatment is safe and can shrink tumors or slow the disease. This is not a cure,…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian cancer
Disease control CompletedThis early-stage trial tested a new drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based chemo. The main goals were to check safety and find the best dose. Researchers als…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough ovarian cancer: drug combo shows promise in clinical trial
Disease control CompletedThis study tested whether adding a new drug called afuresertib to standard chemotherapy (paclitaxel) helps control ovarian cancer that has stopped responding to platinum-based treatments. About 150 women with this hard-to-treat cancer took part. The goal was to see if the combina…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated May 13, 2026 15:58 UTC